
doi: 10.1038/nrc3723
pmid: 25688402
The National Cancer Institute of the United States recently announced a major new initiative in understanding the genomes or, more broadly, the molecular phenotypes of exceptional responders. What can we expect to learn from exceptional responders? What are the potential benefits, and how do we approach studying them?
Cancer Research, Genome, Phenotype, Treatment Outcome, Oncology, Drug Resistance, Neoplasm, Neoplasms, Humans, 1306 Cancer Research, 2730 Oncology, Molecular Targeted Therapy
Cancer Research, Genome, Phenotype, Treatment Outcome, Oncology, Drug Resistance, Neoplasm, Neoplasms, Humans, 1306 Cancer Research, 2730 Oncology, Molecular Targeted Therapy
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 37 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
